Mohamadreza Ahmadifard

Dr. Mohamadreza Ahmadifard


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 December 2022 in Experimental Cell Research
Verified
Journal Article
Closed access
MKMohammad Javad Kamali
Mohammad Javad Kamali
MSMohammad Salehi
Mohammad Salehi
SFSomayeh Fatemi
Somayeh Fatemi
FMFereshteh Moradi
Fereshteh Moradi
AKAzin Khoshghiafeh
Azin Khoshghiafeh
MAMohamadreza Ahmadifard
Mohamadreza Ahmadifard

15 July 2025 in Computers in Biology and Medicine
Verified
Journal Article
Closed access
MKMohammad Javad Kamali
Mohammad Javad Kamali
FSFatemeh Saeedi
Fatemeh Saeedi
AKAzin Khoshghiafeh
Azin Khoshghiafeh
MMMahsa Aghajani Mir
Mahsa Aghajani Mir
CACena Aram
Cena Aram
MAMohamadreza Ahmadifard
Mohamadreza Ahmadifard

30 August 2024 in Heliyon
Verified
Journal Article
Open access
MSMina Shahpari
Mina Shahpari
MHMohamadReza Hashemi
MohamadReza Hashemi
TYTayebeh Younesirad
Tayebeh Younesirad
AHAida Hasanzadeh
Aida Hasanzadeh
MMMohammad Mahdi Mosanne
Mohammad Mahdi Mosanne
MAMohamadreza Ahmadifard
Mohamadreza Ahmadifard
Circular RNAs are noncoding RNAs with circular conformation mainly due to backsplicing event. CircRNAs can potentially impact cell biological processes by interacting with cell signaling pathways. Numerous circRNAs have been found to be aberrantly expressed in a variety of cancers. These RNAs can act as ceRNA (competitive endogenous RNA) by sponging certain miRNAs to form circRNA/miRNA/mRNA networks. Dysregulation of ceRNA networks may lead to dysfunctions in various cell pathways, which modulate apoptosis-associated genes and ultimately result in cancer progression.

3 November 2023 in Advances in Medical Sciences
Verified
Journal Article
Closed access
PSParisa Sahranavard-Pirbazari
Parisa Sahranavard-Pirbazari
AKAzin Khoshghiafeh
Azin Khoshghiafeh
MKMohammad Javad Kamali
Mohammad Javad Kamali
HEHanieh Esfandiar
Hanieh Esfandiar
MBMarzieh Bakhtiari
Marzieh Bakhtiari
MAMohamadreza Ahmadifard
Mohamadreza Ahmadifard

1 July 2026 in Genes & Diseases
Verified
Journal Article
Open access
SEShayan Emami
Shayan Emami
AMAmirreza Mazloomi
Amirreza Mazloomi
FZFatemeh Ziadloo
Fatemeh Ziadloo
SHShaghayegh Hosseinzadeh
Shaghayegh Hosseinzadeh
HSHassan Saeedi
Hassan Saeedi
MAMohamadreza Ahmadifard
Mohamadreza Ahmadifard
The myosin heavy chain 9 (MYH9) gene encodes non-muscle myosin heavy chain IIA (NMIIA), a vital protein involved in fundamental cellular activities, including movement, cell division, and signal transmission. Mutations in MYH9 were initially linked to autosomal dominant disorders collectively termed MYH9-related diseases (MYH9-RD). In recent years, MYH9 has gained significant attention for its pivotal roles in various cancers. However, despite extensive research, its exact contributions to cancer progression remain incompletely understood. Targeting MYH9 through approaches such as non-coding RNAs, small molecules, or gene therapy presents a promising avenue for advancing cancer treatment. Additionally, the dual role of MYH9 in MYH9-RD and cancer raises the intriguing question: are individuals with MYH9 mutations predisposed to or protected from cancer? This review aims to present the structure, functional significance, and clinical associations of MYH9, with an emphasis on its contributions to MYH9-RD and cancer progression. Furthermore, it examines MYH9’s regulatory interactions with non-coding RNAs and its potential applications as a therapeutic target, offering insights into strategies such as RNA interference and CRISPR-based gene editing for cancer treatment.

14 May 2025 in Network Modeling Analysis in Health Informatics and Bioinformatics
Verified
Journal Article
Closed access
PDF file
EKEsmail Karami
Esmail Karami
FRFatemeh Rostamkhani
Fatemeh Rostamkhani
MAMaasoume Abdollahi
Maasoume Abdollahi
MAMohamadreza Ahmadifard
Mohamadreza Ahmadifard